The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma

@article{Ishida2006TheCA,
  title={The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma},
  author={Takashi Ishida and Takefumi Ishii and Akihito Inagaki and Hirohisa Yano and Shigeru Kusumoto and Masaki Ri and Hirokazu Komatsu and Shinsuke Iida and Hiroshi Inagaki and Ryuzo Ueda},
  journal={Leukemia},
  year={2006},
  volume={20},
  pages={2162-2168}
}
Here, we report that tumor cells from some patients (23.8%) with Hodgkin lymphoma (HL) are positive for CC chemokine receptor 4 (CCR4). We therefore tested the chimeric anti-CCR4 monoclonal antibody (mAb), KM2760, the Fc region of which is defucosylated to enhance antibody-dependent cellular cytotoxicity (ADCC), as a novel immunotherapy for refractory HL. KM2760 demonstrated a promising antitumor activity in the CCR4-positive HL-bearing mouse model in the therapeutic setting. Although KM2760… CONTINUE READING
22 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…